ERBB2 and breast carcinoma: Prospective comparative trials have demonstrated that the recurrence score (RS) based on a 21-gene assay was useful for identifying patients with ER-positive, HER2-negative early breast cancer who could be spared multidrug cytotoxic chemotherapy [2–4].